Milataxel

N/A

Report date: 2025/04/18 16:05:56
NME

Base Information

Drug NameMilataxel
Drug Alias NameMAC-321TL-139TL-00139MAC-321 IV
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTropomyosin-related kinase inhibitorsProto-oncogene tyrosine-protein kinase ROS inhibitorsAnaplastic lymphoma kinase inhibitors
TargetsTropomyosin-related kinaseProto-oncogene tyrosine-protein kinase ROSAnaplastic lymphoma kinase
Therapy Area/IndicationsNeoplasm MetastasisCarcinoma, Non-Small-Cell LungLung Neoplasms +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesSuzhou Teligene Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesSuzhou Teligene Ltd
Inactive CompaniesWyeth LlcTaxolog Inc
Active IndicationsNeoplasm Metastasis
Inactive IndicationsCarcinoma, Non-Small-Cell LungLung NeoplasmsRectal Neoplasms +[7] 

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBank